Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.

[1]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[2]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[3]  A. Renshaw,et al.  Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .

[4]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[5]  S. Freedland,et al.  Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. , 2004, The Journal of urology.

[6]  J. Hanley,et al.  Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. , 2004, Journal of Urology.

[7]  D. Grignon,et al.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Ming-Hui Chen,et al.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2003, Journal of the National Cancer Institute.

[9]  A. Renshaw,et al.  Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Hanlon,et al.  Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[11]  D. Hussey.  American Society for Therapeutic Radiology and Oncology , 2001 .

[12]  R. Dunn,et al.  Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. , 2000, International journal of radiation oncology, biology, physics.

[13]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[14]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[15]  A. Hanlon,et al.  Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. , 1996, International journal of radiation oncology, biology, physics.

[16]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[17]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[18]  D. Cox.  Regression Models and Life-Tables , 1972 .